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Abstract
Most studies on probiotics aim to restore intestinal homeostasis to reduce immune-pathology in disease. Of equal
importance are studies on how probiotics might prevent or delay disease in healthy individuals. However, knowledge on
mechanisms of probiotic actions in healthy individuals is scarce. To gain more insight in how different bacterial strains may
modulate the healthy intestinal immune system, we investigated the effect of the food derived bacterial strains L. plantarum
WCFS1, L. salivarius UCC118, and L. lactis MG1363, on the intestinal regulatory immune phenotype in healthy mice. All three
bacterial strains induced an upregulation of activity and numbers of CD11c+ MHCII+ DCs in the immune-sampling Peyer’s
Patches. Only L. salivarius UCC118 skewed towards an immune regulatory phenotype in the small intestinal lamina propria
(SILP). The effects were different in the large intestine lamina propria. L. salivarius UCC118 induced activation in both CD4
and CD8 positive T-cells while L. plantarum WCFS1 induced a more regulatory phenotype. Moreover, L. plantarum WCFS1
decreased the Th1/Th2 ratio in the SILP. Also L. lactis MG1363 had immunomodulatory effects. L. lactis MG1363 decreased
the expression of the GATA-3 and T-bet in the SILP. As our data show that contradictory effects may occur in different parts
of the gut, it is recommended to study effects of probiotic in different sites in the intestine. Our strain-specific results
suggest that unspecified application of probiotics may not be very effective. Our data also indicate that selection of specific
probiotic strain activities on the basis of responses in healthy mice may be a promising strategy to specifically stimulate or
suppress immunity in specific parts of the intestine.
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Introduction
Intestinal microorganisms are of essential importance for the
development and maintenance of homeostasis of both the
intestinal and peripheral immune system [1,2]. This is illustrated
by the fact that an altered microbiota is associated with the
development of intestinal infections and inflammatory bowel
disease (IBD) [3,4]. Modification of the intestinal microbiota by
administration of probiotic bacteria, such as Lactobacillus or
Bifidobacterium species, is a promising strategy to prevent or
overcome excessive intestinal inflammation and to restore immune
homeostasis [5–9]. The efficacy of probiotics in the treatment of
intestinal inflammation has been demonstrated in a range of
experimental disease models [10–12], as well as in patients
suffering from intestinal inflammatory diseases [13–17].
Besides the beneficial effects of probiotics in inflammatory
disease, the disease-preventing potential of probiotic bacteria is
gaining attention [18–21]. Probiotic treatment may benefit
individuals who are not yet receiving medical treatment, but are
at risk of developing disease due to age- [22], obesity- [23],
malnutrition- [24], or stress-related [25] deterioration of immune
homeostasis. Surprisingly, the number of studies describing the
immunomodulatory effects of probiotic bacteria in non-diseased
individuals is small [18–21]. Most studies have focused on the
diseased situation to demonstrate the efficacy of probiotic
treatment [5–9,13–17]. However, due to immune pathology
[26,27] and a disruption of the intestinal barrier [28], these
studies may not reflect or predict the immunomodulatory effects of
probiotics in healthy individuals or persons with sub-optimal
immune health. Studying how different bacterial strains influence
the immune system in the healthy intestine will provide insight in
the mechanisms of beneficial effects of probiotics in the intestine.
Further, it will provide insight in the strain dependency of
probiotic treatment, their safety, as well as potential applications
for improving or maintaining immune health. For these reasons,
we decided to investigate the immunomodulatory effects of
probiotic bacteria in healthy, non-diseased mice.
It is hypothesized that in the intestine, probiotics influence the
intestinal immune response through several different pathways: i)
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probiotic sampling in the Peyer’s Patches (PP), influencing
dendritic cell (DC) and T cell responses in and beyond the PP;
(ii) probiotic-interaction with small intestine lamina propria (LP)
DCs, of which at least two specialized subsets can be discriminat-
ed, CD103+CX3CR1
2 DCs and CD1032CX3CR1
+ DCs [29],
influencing LP T cell responses; and (iii) probiotic-interaction with
epithelial cells, influencing DC and T cell responses in the LP
through the secretion of cytokines [30,31]. Although most of the
research on probiotic-induced immune signaling has focused on
the small intestine [32], also the large intestinal LP is an
immunological effector site [33] in which changes are associated
with the development of inflammatory bowel diseases, such as
ulcerative colitis.
In the present study we investigated the distribution of DC and
T cell subsets at different intestinal induction and effector sites
[peyers patches (PP), small intestinal LP (SILP) and in the large
intestinal LP (LILP)] after administration of L. plantarum WCFS1
[21], L. salivarius UCC118 [20], and L. lactis MG1363 [34] to
healthy mice. The bacteria were administered over 5 days,
covering the period required for mice to develop an adaptive
immune response [18,35]. In this study, we demonstrated strain-
dependent effects of the bacterial treatments on DC and T cell
activation in the PP, SILP and LILP, as well as reduction of the
Th1/Th2 ratio in the small intestinal LP. We demonstrated that L.
salivarius UCC118 and L. plantarum WCFS1 have the strongest
immunomodulating capacities of the three tested bacterial strains.
L. salivarius UCC118 skews the balance between effector and
regulatory T cells towards an immune regulatory phenotype in the
small intestinal LP while simultaneously activating T-cells in the
large intestinal LP. L. plantarum WCFS1 skews the balance towards
an immunoregulatory phenotype in the large intestinal LP, while
at the same time this probiotic shifted the Th1/Th2 balance
towards Th2 in the small intestine LP. This warrants caution in
drawing conclusions about the type of immunomodulating
capacity of a specific strain when only one location in the intestine
is studied. Although less pronounced, also L. lactis MG1363 had
immunomodulating effects.
Materials and Methods
Bacterial Strains and Growth Conditions
L. plantarum WCFS1 [36] and L. salivarius UCC118 [37] were
cultured at 37uC in Man, Rogosa, and Sharpe (MRS) broth. L.
lactis MG1363 [38] was cultured at 30uC in M17 broth containing
0.5% glucose. All bacterial cultures were grown overnight until the
stationary phase of growth was reached. Subsequently, the cultures
were diluted 1:1000 in fresh medium and cultured for a second
night. The optical density at 600 nm was measured and the
number of colony forming units (CFU) was calculated based on
standard growth curves. For all cultured bacterial strains, an
OD600-value of 1 corresponds to 1–2610
9 CFU/mL, which was
confirmed by plating serial dilutions on MRS or M17 agar plates.
To avoid bacterial alteration and cell death, extensive washing and
centrifugation was avoided. After overnight growth, bacteria were
diluted in fresh, sterile MRS and immediately administrated to the
animals. The mice received either sterile MRS as a control or 1–
26108 CFU bacteria in 200 mL MRS via intragastric gavage,
daily.
Animals and Tissue
Wild-type male Balb/c mice were purchased from Harlan
(Harlan, Horst, The Netherlands). The animals were fed standard
chow and water ad libitum. All animal experiments were performed
after receiving approval of the institutional Animal Care
Committee of the Groningen University (DEC5644B). All animals
received animal care in compliance with the Dutch law on
Experimental Animal Care.
To study the effect of three bacterial strains on the systemic
immune system (L. lactis MG1363, L. salivarius UCC118, and L.
plantarum WCFS1) or that of MRS broth, a 200 ml volume sample
was administered by intragastric gavage of once daily for five
consecutive days [18]. At day six, the mice were sacrificed, after
which the intestine was removed for further analysis. A tissue
sample from the middle of the small intestine (i.e. ileum) was snap
frozen in liquid nitrogen for RNA isolation and quantitative real-
time PCR. Due to restrictions in the cellular yield, only the PP,
SILP and the large intestine were used for cell isolations. The
LILP cell yield was not high enough to allow accurate analyses of
(activated) (CD103+) dendritic cell frequencies. Therefore, only T
cell subsets were analyzed in the LILP.
Cell Isolation
After sacrificing the mice, the intestine was removed and rinsed
with ice cold PBS. PPs were removed from the tissue and single
cell suspensions were made by mechanical disruption of the tissue
between two glass slides in 1 mL of ice cold RPMI containing 10%
heat inactivated fetal calf serum (FCS). Subsequently, a cell
strainer was used to remove remaining cell clumps.
The small and large intestine were cut in small pieces and rinsed
three times in ice cold Phosphate Buffered Saline (PBS). Epithelial
cells were removed by incubation of the tissue in PBS containing
10% heat inactivated FCS, 1 mM Sodium Pyruvate, 10 mM
Ethylenediaminetetraacetic (EDTA) and 20 mM 4-(2-hydro-
xyethyl)-1-piperazine-ethanesulfonic acid (HEPES) (pH 7.4) for
30 minutes at 37uC. Subsequently, the tissue was washed in ice
cold PBS. The LP was removed by incubation of the tissue in
RPMI 1640 medium, containing 10% heat inactivated FCS,
1.5 mg/mL Collagenase D (Sigma Aldrich), and 10 mg/mL
Table 1. Antibodies used for flow cytometry.
Specificity
Clone
Name Fluorochrome Dilution Supplier
CD3 17A2 Pacific Blue 200x BioLegend
CD4 RM4–5 PerCP 200x BioLegend
CD8 53-6.7 Alexa700 50x BioLegend
CD25 3C7 APC 100x BioLegend
CD69 H1.2F3 PE 200x BioLegend
FoxP3 FJK-16S FITC 100x eBioscience
Rat IgG2b N/A APC 100x BioLegend
Hamster IgG N/A PE 200x BioLegend
Rat IgG2a N/A FITC 100x eBioscience
CD11c N418 APC 25x BD Biosciences
MHC II 2G9 Biotin +
streptavidin PerCP
150x BD Biosciences
CD19 6D5 PE-Cy7 100x BioLegend
CD80 16-10A1 PE 50x BioLegend
CD86 PO3 Alexa700 50x BioLegend
CD103 2E7 Pacific Blue 25x BioLegend
Hamster IgG N/A PE 50x BioLegend
Rat IgG2b N/A Alexa700 50x BioLegend
Hamster IgG N/A Pacific Blue 25x BioLegend
doi:10.1371/journal.pone.0068952.t001
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DNAse I (Sigma Aldrich), for 60 minutes at 37uC. The reaction
was terminated by the addition of EDTA to a final concentration
of 10 mM. The cell suspension was washed in ice cold PBS. A cell
strainer was used to remove remaining cell clumps.
Lymphocytes were enriched and dead cells were removed from
the PP and LP mixtures by resuspension in 20% percoll and
loading on a 55%, 45%, and 35% percoll gradient (GE
Healthcare, Eindhoven, the Netherlands). Gradients were centri-
fuged at room temperature for 30 minutes at 800 g. The interface
containing live cells was collected and washed in ice cold PBS,
before cell counting and staining. After density gradient centrifu-
Figure 1. Dendritic cells were gated in the forward side scatter plot, based on size and granularity. CD19+ B-cells were excluded from
analysis and the frequency of MHC II+ CD11c+ cells was determined. Within the DC populations CD80, CD86, or CD103 isotype controls were used to
set the gate to 99% negative cells. This gate was copied to the samples stained for CD80, CD86, and CD103 and the frequency of positive cells was
determined.
doi:10.1371/journal.pone.0068952.g001
Table 2. Primer sequences used for quantitative real-time PCR.
Transcript Forward Primer Reverse Primer
T-bet GCCAGGGAACCGCTTATATG GACGATCATCTGGGTCACATTGT
GATA-3 AGGCAAGATGAGAAAGAGTGCCTC CTCGACTTACATCCGAACCCGGTA
RORcT CACGGCCCTGGTTCTCAT CAGATGTTCCACTCTCCTCTTCTCT
IL4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA
IL5 AGCACAGTGGTGAAAGAGACCTT TCCAATGCATAGCTGGTGATTT
IL10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT
IL12p40 GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG
IL17 ATCAGGACGCGCAAACATGA TTGGACACGCTGAGCTTTGA
IL23p19 TGTGCCCCGTATCCAGTGT CGGATCCTTTGCAAGCAGAA
IFNc TCCTGCAGAGCCAGATTATCTC CTCGGATGAGCTCATTGAATGC
TGFb GGGCTACCATGCCAACTTCTG GAGGGCAAGGACCTTGCTGTA
doi:10.1371/journal.pone.0068952.t002
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gation, more than 90% of the cells were vital, which was
confirmed by propidium iodide staining.
Cell Staining
T cell stainings were performed on single cell suspensions
retrieved from the Peyer’s patches (PP), small intestinal LP (SILP),
and large intestinal LP (LILP). DC stainings were performed on
cells retrieved from the PP and SILP. The T cell cocktail
contained monoclonal antibodies directed against CD3, CD4,
CD8, CD25, CD69, FoxP3, or appropriate isotype controls
(Table 1). The DC cocktail contained monoclonal antibodies
directed against CD11c, MHC II, CD19, CD80, CD86, CD103,
or appropriate isotype controls (Table 1).
Briefly, 16106 cells were incubated in FACS buffer (PBS
containing 2% heat-inactivated FCS) containing 10% normal
mouse serum for 30 minutes to prevent non-specific antibody
staining. Subsequently, the cells were incubated with a cocktail of
primary antibodies for 30 minutes, in the dark, after which the
cells were washed in ice cold FACS buffer twice. Tubes stained for
T cells were subsequently fixed in ice cold 16FACS Lysing
solution (BD Biosciences) for 30 minutes in the dark and washed
twice in permeabilisation buffer (eBioscience). Subsequently, the
cells were incubated with the anti-FoxP3 antibody or the isotype in
permeabilisation buffer containing 2% rat serum for 30 minutes in
the dark. Then the cells were washed twice in ice cold
permeabilisation buffer and resuspended in FACS buffer until
FACS analysis. Tubes for DC staining were washed twice in ice-
cold FACS buffer, after which the cells were incubated with the
secondary step for 30 minutes in the dark. Subsequently, the cells
were fixed in ice cold FACS Lysing solution for 30 minutes in the
dark followed by washing twice in ice cold FACS buffer and
resuspended in FACS buffer until FACS analysis (within 24 hours).
The whole procedure was performed on ice.
Flow Cytometry
At least 56105 cells were analyzed by flow cytometry. Flow
cytometry was performed using the LSR II Flow Cytometer
system (BD Pharmingen), with FACS Diva software. Analysis was
performed using FlowJo 7.6.2 software.
Dendritic cells were gated in the forward side scatter plot, based
on size and granularity, CD19+ B-cells were excluded from
analysis and the frequency of MHC II+ CD11c+ cells was
determined (Figure 1). Within the DC populations CD80,
CD86, or CD103 isotype controls were used to set the gate to
99% negative cells. This gate was copied to the sample stained for
CD80, CD86, and CD103 and the frequency of positive cells was
determined (Figure 1). DCs were defined as CD11c+MHC II+
cells. Intestinal DCs are depicted as the frequency of CD103+ cells
within the CD11c+MHC II+ population. CX3CR1
+ DCs were
defined as CD11c+ MHC II+ CD1032 DCs. Also the frequency of
activated DCs was determined and expressed as the frequency of
Figure 2. Effects of three bacterial strains on Peyer’s Patch dendritic cells. Frequency of CD11c+ MHC II+ dendritic cells (A), CD103+
dendritic cells (B), CD80+ dendritic cells (C), or CD86+ dendritic cells (D) in the Peyer’s Patches following treatment with culture medium (white bars)
(N = 6), L. lactis MG1363 (dashed bars) (N = 6), L. plantarum WCFS1 (grey bars) (N = 6), or L. salivarius UCC118 (black bars) (N = 6). CD103, CD80, and
CD86 frequencies are expressed as the frequency of cells within the CD11c+ MHC II+ population. Results are expressed as the mean6 standard error
of the mean (SEM). Statistical significance was calculated using the Students t- test. * represents P-values ,0.05.
doi:10.1371/journal.pone.0068952.g002
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CD80+ or CD86+ cells within the CD11c+MHC II+ cell
population.
Lymphocytes were gated in the forward side scatter plot and the
frequency of CD3+ T cells was determined. Within the T cell
population the frequency of CD8+ T cells and CD4+ T cells was
determined. Within both the CD4 and CD8 T cell population the
isotype controls for CD69 or CD25 were used to set the gate to
99% negative cells. This gate was then copied to the sample
stained for CD69 or CD25 and the frequency of positive cells was
determined.
Regulatory T cells are defined based on the expression of CD25
and the transcription factor FoxP3. For this, FoxP3+ cells were
gated within the CD4 T cell population (within the CD4 T cell
population the FoxP3 isotype control was used to set the gate to
99% negative cells). It has been shown by us and others that these
cells express regulatory cytokines [39,40]. This gate was copied to
the sample stained for FoxP3 and the frequency of positive cells
was determined. The expression of CD25 in these cells was
confirmed. All CD4+FoxP3+ cells consistently demonstrated CD25
expression. Results are expressed as the frequency of
Figure 3. Effects of three bacterial strains on Peyer’s Patch T cells. Frequency of CD69+ CD4 T cells (A), regulatory T/effector T cell ratio (B),
CD25+ FoxP3- effector CD4 T cells (C), CD25+ FoxP3+ regulatory T cells (D), or CD69+ CD8 T cells (E) in the Peyer’s Patches following treatment with
culture medium (white bars) (N= 6), L. lactis MG1363 (dashed bars) (N = 6), L. plantarum WCFS1 (grey bars) (N = 6), or L. salivarius UCC118 (black bars)
(N = 6). Results are expressed as the mean 6 standard error of the mean (SEM). Statistical significance was calculated using the Students t-test. *
represents P-values ,0.05.
doi:10.1371/journal.pone.0068952.g003
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CD25+FoxP3+ cells within the total CD4 T cell population
(CD4+CD3+ cells). Effector T cells are defined as the frequency of
CD25+FoxP32 or CD69+ cells within the CD4+CD3+ (T helper
cells) or CD8+CD3+ (cytotoxic T cells; CTLs) population.
qRT-PCR
mRNA of immunological genes was detected by quantitative
reverse transcribed PCR (qRT-PCR). The tissues (N=6 per
group) were lyzed in Trizol lysing buffer (Invitrogen). Total
RNA was extracted by chloroform-isopropanol extraction. cDNA
was prepared from isolated RNA using SuperscriptTM II Reverse
Transcriptase according to the kit protocol (Invitrogen). Quanti-
tative real time RT-PCR was performed on the ABI7900 Taqman
(Applied Biosystems) using a two-step amplification protocol. PCR
reactions contained 10 ng/mL of cDNA as template, 1.5 mM
forward and reverse primer and SYBR Green PCR master mix
(Applied Biosystems) in a total reaction volume of 20 mL. All PCR
reactions were performed in triplicate. Relative gene expression
was normalized to the GAPDH expression (DCt=CtGENE OF
INTEREST- CtGAPDH) of the same sample and depicted as inverted
relative expression levels [1/DCt (A.U.)]. Primer sequences are
described in Table 2. All PCR reactions were optimized using
RNA isolated from the spleens of untreated Balb/c mice.
Statistics
Flow cytometry data results are expressed as the mean 6
standard error of the mean (SEM). Normal distribution of the data
sets was confirmed by the Kolmogorov-Smirnov test. The two-
sided Students t-test was used to determine changes in immune cell
populations after probiotic treatment. Gene expression data are
expressed as the median (range). The Th1/Th2 ratio was
evaluated by dividing the gene expression of T-bet by gene
expression of GATA-3. The two-sided Mann Whitney U-test was
used to determine changes in expression profiles after probiotic
treatment in vivo. P-values ,0.05 (*) were considered statistically
significant.
Figure 4. Effects of administration of three types of bacterial strains on the small intestinal LP (SILP) dendritic cells. Frequency of
CD11c+ MHC II+ dendritic cells (A), CD103+ dendritic cells (B), CD80+ dendritic cells (C), or CD86+ dendritic cells (D) in the SILP following treatment
with culture medium (white bars) (N = 6), L. lactis MG1363 (dashed bars) (N = 6), L. plantarum WCFS1 (grey bars) (N = 6), or L. salivarius UCC118 (black
bars) (N = 6). CD103, CD80, and CD86 frequencies are expressed as the frequency of cells within the CD11c+ MHC II+ population. Results are
expressed as the mean 6 standard error of the mean (SEM). Statistical significance was calculated using the Students t- test. * represents P-values
,0.05.
doi:10.1371/journal.pone.0068952.g004
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Results
Probiotic Treatment Induces DC and T cell Activation in
the Small Intestinal PP
We evaluated the immunomodulatory properties of L. plantarum
WCFS1, L. salivarius UCC118, and L. lactis MG1363 in vivo. These
strains were selected for their high IL10 inducing potential in
murine bone marrow derived dendritic cells as shown in a
previous study from our group [18]. We first focused on the
Peyer’s Patches (PP), the mucosal sites for induction of adaptive
immune responses [41]. The mice (N=6 per group) received the
bacteria, or culture medium alone as a control, for 5 consecutive
days.
In the PP, the first immune cells to respond to transcytosed
antigens are the dendritic cells in the dome area, underlying the
follicular epithelium [41]. All bacteria-treated groups demonstrat-
ed increased CD11c+ MHC II+ dendritic cell frequencies in the PP
as compared to the medium treated mice (Figure 2A). The
percentage of CD103+ intestinal DCs was increased, while the
percentage of CD103- intestinal DCs (i.e. CX3CR1
+ DCs; results
not shown) was decreased, but both only reached statistical
significance after L. salivarius UCC118 administration (Figure 2B).
Figure 5. Effects of administration of three types of bacterial strains on the small intestinal LP (SILP) T cells. Ratio of regulatory T/
effector T cells (A), frequency of CD25+ FoxP3- effector CD4 T cells (B), CD25+ FoxP3+ regulatory T cells (C), CD69+ CD4 T cells (D), CD69+ CD8 T cells
(E) in the SILP following treatment with culture medium (white bars) (N = 6), L. lactis MG1363 (dashed bars) (N= 6), L. plantarum WCFS1 (grey bars)
(N = 6), or L. salivarius UCC118 (black bars) (N = 6). Results are expressed as the mean 6 standard error of the mean (SEM). Statistical significance was
calculated using the Students t- test. * represents P-values ,0.05.
doi:10.1371/journal.pone.0068952.g005
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Although no effect of probiotic treatment was observed on %
CD80+ DCs in the PP (Figure 2C), the treatment with L. plantarum
WCFS1 and L. salivarius UCC118, but not L. lactis MG1363 did
increase the activation status of the dendritic cells in the PP as
demonstrated by increased frequencies of CD86+DCs (Figure 2D).
These changes in the DC compartment of the PP coincided with a
twofold increase in early activated CD4 T cells, as demonstrated
by increased CD69+ CD4 T cell frequencies following L. plantarum
WCFS and L. salivarius UCC118 (fig 3A) and L. lactis MG1363
treatment (Figure 3A) and increased percentage of CD25+ cells
after L. salivarius UCC118 treatment as compared with medium
treatment (Figure 3C). The balance between effector CD4 T cells
and regulatory T cells in the PP (Figure 3B and 3D) was not
changed. The frequency of early-activated CD69+ CD4 T cells in
the CD8+ compartment was strongly increased by L. plantarum
WCFS and L. salivarius UCC118 treatment but not by L. lactis
MG1363 treatment (Figure 3E).
L. salivarius UCC118 but not L. plantarum WCFS or  
Phenotype in the Small Intestinal LP
Next, we questioned whether the intestinal effector sites are
altered by the bacterial treatments. For this, we studied the
distribution of immune cell populations in the small intestinal LP
(SILP). In addition to analysis of DC and T cell subsets by flow
cytometry, the expression levels of T cell polarizing cytokines were
determined by quantitative real-time RT-PCR as a measure for
specific T effector cell responses.
None of the bacterial treatments significantly altered the
frequency of total DCs (Figure 4A), CD103+ (Figure 4B) or
CD1032 (not shown) DCs in the SILP. We did observe however a
strong reduction of the CD80+ dendritic cells in the SILP after L.
plantarum WCFS and L. salivarius UCC118 treatment. This
however only reached statistical significant differences with L.
salivarius UCC118 (Figure 4C) in the SILP. These effects were less
pronounced on the CD86+ expressing DC compartment
(Figure 4D).
L. salivarius UCC118 treatments skewed the balance between
effector and regulatory T cells to a more regulatory phenotype
(Figure 5C). In the L salivarius UCC118 treated animals, this
altered balance was caused by a pronounced decrease of effector T
cell frequencies (Figure 5B), combined with an increased
regulatory T cell frequencies (Figure 5A).
The frequency of activated CD69+ CD4 T cells and activated
CD8 T cells (Figure 5D, 5E) increased in most cases but was
variable and did, therefore, not reach statistical significant
differences.
L. lactis MG1363 and L. plantarum WCFS1 Treatment
Decreases Th1 and Th2 Specific Cytokine Expression in
the Small Intestinal LP
By PCR we quantified the expression of T-bet, GATA-3,
RORcT, IL4, IL5, IL10, IL12p40, IL17, IL23p19, IFNc, TGFb
in the SILP. We found only statistical significant changes in T cell
polarization transcription factors. The expression of the Th2-
specific transcription factor GATA-3 was significantly decreased in
response to L. lactis MG1363 and L. plantarum WCFS1 treatment
(P,0.05) (Table 3). Although, these 2 bacterial strains also
decreased the expression of the Th1 transcription factor T-bet
(P,0.05) (Table 3), the resulting Th1/Th2 ratio was decreased in
both cases, illustrating a more pronounced skewing towards Th2.
This Th1/Th2 ratio decrease only reached statistical significance
after treatment with L plantarum WCFS1.
Th17 transcription factor RORcT transcripts were abundantly
present in the SILP, but the expression levels were not changed by
the probiotic treatments (Table 3). Similarly, IL17 expression was
not influenced by probiotic treatment (data not shown). Expression
of the Th1 cytokines IL12p40 and IFNc was low. The regulatory
IL10 and FoxP3 transcripts were low and not altered by the
treatments (data not shown). TGFb, which is involved in both T
cell skewing towards a regulatory phenotype as well as skewing
towards a Th17 phenotype [42], was abundantly present in the
SILP (Table 3) but not altered by the probiotic treatments. The
expression levels of the cytokines IL-4 and IL-5 were not detected
or in very low levels and were not affected by probiotic treatment
(results not shown).
Probiotic Treatment Induces T cell Activation in the Large
Intestinal LP
Although the mucosal interface of the large intestine is much
smaller than that of the small intestine, the LP of the large intestine
(LILP) is also considered an immune effector site. On average,
746,00067875 cells were retrieved from the LILP, which was too
low to allow for reliable quantification of changes in the small DC
compartment. Therefore, only changes in the T cell compartment
were analysed.
The effects were strain dependent. The frequency of regulatory
T cells was significantly enhanced by L. plantarum WCFS1
treatment (Figure 6A). As a consequence the regulatory-effector
balance after L. plantarum WCFS1 treatment showed a trend
towards a more regulatory environment in the LILP (p = 0.07)
(Figure 6C). However, both L. plantarum WCFS1 and L. salivarius
UCC118 treatment enhanced CD4 and CD8 T cell activation, as
demonstrated by increased frequencies of CD69+ expressing cells
(Figure 6D and 6E respectively). L. lactis MG1363 treatment had
no effect on LILP CD4 and CD8 T cells (Figure 6).
Table 3. Gene expression levels in the small intestine lamina propria.
Transcript Medium L. lactis MG1363 L. plantarum WCFS1 L. salivarius UCC118
T-bet 0.09371360.007254 0.04503460.016484* 0.02641460.017406* 0.05855660.025691
GATA3 0.0858460.01587 0.03508660.018961* 0.03216160.016688*
Th1/Th2 ratio 1.24472760.226619 1.18964460.555112 0.39656560.25265* 0.86435360.333015
RORcT 0.17344560.028785 0.18539960.018323 0.18425960.006646 0.20905860.036537
TGFb 0.13074560.05392 0.13649160.024243 0.13161360.007886 0.19800260.068527
Of all primer sequences shown in Table 2, only T-bet and GATA-3, RORcT and TGBb were detected and are shown in this table. By dividing T-bet through GATA-3
expression the Th1/Th2 ratio is calculated.
*represents P-values ,0.05.
doi:10.1371/journal.pone.0068952.t003
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lactis      MG1363 Skews T cells Towards a Regulatory
L.
Discussion
The majority of probiotics are marketed for consumption by
healthy individuals to prevent disease. However, to date most
experimental studies have focused on specific intestinal disease
models to demonstrate the efficacy of probiotics [10–12]. In these
models, the intestinal immune barrier may be compromised,
altering the contact between the probiotic bacteria and the
intestinal immune cells [28,43,44]. Moreover, in these models,
immune homeostasis is strongly perturbed and playing a role in
the pathophysiology of the disease [26,27]. Although these models
provide valuable insight into the efficacy of the probiotic
treatment, they do not reflect or predict the immunomodulatory
properties in the healthy situation. For this reason, we decided to
study the intestinal immunomodulatory effects of different
bacterial strains in healthy mice. The chosen strains are food-
derived bacteria [20] with confirmed immunomodulating effects in
the murine systemic circulation [18,40] and on ex vivo dendritic
cells [40,45–47].
To our knowledge, this is the first report on differential location-
specific immune changes in the intestine following short-term
treatment with probiotics. After administration of the three
bacterial species we always observed an upregulation and
increased activity of DC’s in the PP illustrating an enhanced
Figure 6. Effects of administration of three types of bacterial strains on the large intestinal LP (LILP) T cells. Frequency of CD25+
FoxP3+ regulatory T cells (A), CD25+ FoxP3- effector CD4 T cells (B), ratio of regulatory T/effector T cells (C), CD69+ CD4 T cells (D), or CD69+ CD8 T
cells (E) in the LILP following treatment with culture medium (white bars) (N = 6), L. lactis MG1363 (dashed bars) (N = 6), L. plantarum WCFS1 (grey
bars) (N = 6), or L. salivarius UCC118 (black bars) (N = 6). Results are expressed as the mean6 standard error of the mean (SEM). Statistical significance
was calculated using the Students t- test. * represents P-values ,0.05.
doi:10.1371/journal.pone.0068952.g006
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activity in this immune sampling site. L. salivarius UCC118
treatment skewed the adaptive immune balance towards a
regulatory phenotype in the SILP, but not in the LILP (both
immune effector sites). This was different with L. plantarum
WCFS1. L. plantarum WCFS1 had almost no effects on regulatory
cells in the SILP but shifted the Th1/Th2 balance towards Th2 in
the SILP as GATA-3 suppression was less pronounced than T-bet
suppression in the SILP. The effects of L. plantarum WCFS1 were
different in the LILP as here L. plantarum WCFS1 induced an
upregulation of regulatory cells. This was different with L. salivarius
UCC118 where in the LILP only enhanced activation of T-cells
was observed.
Up to now, we and others explained immunomodulatory effects
of probiotics by direct host-probiotic interactions [20,48]. This
explanation was supported by the identification of several effector
molecules on probiotics that can interact with pattern recognition
receptors found on gut epithelial cells or on intestine-bound
immune cells [45]. Although plausible, this theory cannot explain
that the same probiotic has a principally different effect in the
small and large intestine. This observation does fit however in the
theory of the pioneer strategy of probiotic administration.
According to this theory a probiotic does not necessarily become
a residential part of the host microbiome but may benefit other
bacteria in the intestine [49]. As the microbiome composition is
different in the small and large intestine also different effects of
probiotic administration may be expected with, consequently,
different effects on the host immune system. This however should
not be interpreted as a suggestion that direct interaction with the
host is not involved in immunomodulation. We have shown in
previous studies that short-term administration of probiotics, that
cannot induce shifts in the composition microbiota, does result in
immediate host-responses [20]. However, with longer administra-
tion periods such as in the present study location specific changes
in microbiota may occur as well.
In a previous study we showed that probiotics might skew the
peripheral immune response away from Th2 responses in healthy
mice [18,47]. Our present study showed that locally in the SILP
only two of the three strains attenuate Th2 responses. However,
this did not results in a higher Th1/Th2 ratio since in case of L.
plantarum WCFS1 the T-bet expression was more profoundly
suppressed resulting in a threefold decrease in Th1/Th2 ratio. As
the same strains were being used in our previous study and this
study [18] it has to be concluded that local effects on T-cells are
not necessarily reflected in the systemic circulation. This should be
explained by the fact that as shown in our previous study [18]
many processes are activated in the mesenterial lymph nodes and
spleen after probiotic induced immune activation.
Also L. lactis MG1363 had a decreasing effect on GATA-3 and
T-bet, but this did not result in a significant change in the Th1/
Th2 ratio. This effect of L. lactis MG1363 is surprising as L. lactis
MG1363 is not generally considered to be a probiotic strain. This
should change as in addition to effects on Th1 and Th2
differentiation, it also activated dendritic cells in the PP. The
probiotic effects of this strain have also been found in the systemic
circulation in previous studies [18,47].
Sampling of luminal contents may occur through DCs in the PP
[50], goblet cells [51], and LP DCs that exert their dendrites into
the intestinal lumen [41,50]. However, all these studies on
immune sampling focus on luminal particles and not on full
bacteria such as probiotics. It is still largely unknown where
probiotics are sampled. Most likely probiotics are sampled in our
study in the PP as we found increased frequencies of antigen-
presenting DCs and DC activation in the PP and not that
outspoken for all strains in the LP. However, subtle changes in the
LP (CD103+) DC population may be responsible for the previously
observed changes in systemic immunity [18]. However, we should
again emphasize that this might be different in (experimental)
disease models, in which the barrier function is disrupted [28] and
direct contact between the probiotics and immune cells is possible
[44,52].
It might be suggested that advanced in vitro tools [35,46,53–56]
might have been helpful in understanding and predicting the
effects of the strains in the present study. However, we have
applied many of those systems in previous studies [18,40,46,56]
but we had to conclude that the majority of the systems are poor
predictors as the systems focus on the secretion of only one or a
few pro- and anti-inflammatory cytokines from PBMCs or DCs as
a model for immunomodulation in vivo [35,46,53–56]. As shown in
the present study the composition of the gastrointestinal immune
system is very complex as a consequence of which contradictory
effects can be found in different parts of the intestine. To our best
knowledge there are no in vitro models available that have been
designed to mimic the different parts of the intestine.
The decreased Th1/Th2 ratio after L. plantarum WCFS1
treatment in the SILP may suggest that L. plantarum WCFS1
may be effective in the prevention or slowing down the
development of Th2 skewed intestinal diseases [27] in still healthy
individuals. L. salivarius UCC118 may be less effective in this
respect but might theoretically be beneficial for preventing or
slowing down chronic, low grade intestinal immune disorders
which require only a modest adjustment in the Th1/Th2 balance,
or intestinal food allergies that require enhanced immunosuppres-
sion rather than an altered Th1/Th2 balance [57]. However the
differential effects in the SILP and LILP warrant caution in
suggesting the application of L. salivarius UCC118 in disease
models. Especially the enhanced inflammatory responses in the
LILP may be problematic when the barrier is disturbed. This
dualistic effect of L. salivarius UCC118 in different parts of the gut
may also explain the variable performance of L. salivarius UCC118
in disease models [58–60].
In summary, in the current study we demonstrated intestinal
immunomodulation following short-term oral administration of
three bacterial strains in healthy mice. The observation that these
effects on the immune system are strain dependent supports the
need to select probiotics for specific groups of individuals with
different needs instead of generalized application of probiotics for
prevention of any type of disorder. Our data suggest that it may be
mandatory to select strains and test specific probiotics to prevent
allergy (i.e. suppressing Th2 responses) and others for preventing
infection in still healthy individuals (i.e. stimulating Th1 respons-
es). This however should be carefully defined as we show that some
probiotics may have desired effects in the small intestine while
inducing responses of a proinflammatory nature in other parts of
the intestine. Although further research is required, our results
suggest that the selection of specific probiotic strains on the basis of
responses in healthy mice may be a promising strategy to improve
health and prevent specific intestinal immunological disorders.
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